Gold holds near $2,923 as trade war fears boost safe-haven demand. Can it stay above $2,900, or will a strong USD push prices lower?

Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.

Oil prices rebound 2% as Russia's output drops below OPEC+ quota. Will supply cuts and Fed policies push energy markets higher?

Main Street Capital's valuation has surged, trading at a 100% premium to NAV, making it overvalued and justifying a Sell rating despite strong performance. Rising non-accruals, now at 1.4% of fair value and 3.9% of cost, indicate deteriorating fundamentals amidst high valuations. MAIN's share price has appreciated over 25% since July, but future upside is limited due to unsustainable valuation levels.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=128644&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=128642&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Capri Holdings Limited (NYSE:CPRI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=128643&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=128640&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=128641&wire=1 or contact Joseph E. Levi, Esq.

Hims & Hers has shown significant growth, with a 350% stock gain in 2024, driven by subscriber and revenue increases, and positive free cash flow. The company boasts a strong balance sheet with $250M in cash, no debt, and strategic share repurchases, enhancing shareholder value. Future growth is expected from personalized solutions, with the potential to expand the subscriber base by millions and grow revenue per subscriber.

Arm Holdings' entrenched dominance in the mobile market, coupled with several other tailwinds, ensures durable earnings growth for years. Despite a high valuation with a 100 forward non-GAAP PE, ARM's exceptional fundamentals and deep industry partnerships justify a Buy rating. ARM is capitalizing on AI infrastructure build-out and custom silicon development, which has allowed it to break into the data center market.

I recommend a buy rating for Thomson Reuters due to its solid organic growth outlook and sustained margins despite elevated AI-related investments. TRI's 4Q24 results showed a 5.4% y/y organic revenue increase, with the Big 3 segments growing 7.8% y/y organically, reflecting strong demand. AI-enabled products are driving growth, with Westlaw Precision adoption rising to 43% in 4Q24, indicating significant enterprise adoption and future growth potential.

Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.

NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skyworks Solutions, Inc. ("Skyworks Solutions, Inc.") (NASDAQ:SWKS) concerning possible violations of federal securities laws. Skyworks issued a press release on February 5, 2025, reporting its financial results for its fiscal quarter ended December 27, 2024.

WESTLAKE, Texas--(BUSINESS WIRE)--Schwab announces pricing of $13.1B secondary offering of its common stock held by an affiliate of The Toronto-Dominion Bank.

Toyota's low 7.7x P/E ratio and advanced engineering, including AI robots and solid-state batteries, make it an underappreciated investment opportunity. Toyota trades at reasonable PEG ratios around 1.0x and investors see 3.25% of the current market cap spent on R&D compared to 0.39% at Tesla. Toyota is a major player in R&D spend, especially in hybrid cars and solid-state battery technology, boasting over 1000 patents.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Integral Ad Science Holding Corp. (NASDAQ:IAS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/integral-ad-science-lawsuit-submission-form?prid=128630&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128633&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=128635&wire=1 or contact Joseph E. Levi, Esq.